MoneyTree: Nation's Biggest Bioclusters Record Declines in VC Spending in Q2 | GenomeWeb

By Alex Philippidis

The nation's two largest life-sciences clusters joined most of the US in recording declines in venture capital investment in biotechnology and pharmaceutical companies during the second quarter, according to the quarterly MoneyTree Survey released this week.

The period also saw an even sharper falloff in medical device investment, , reflecting continued weakness in the market for financing startups as the economy continues to slump, the report notes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.